The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
VEGF as a Key Mediator of Angiogenesis in Cancer
Abstract
Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein with a molecular weight of approximately 45 kDa. It is the key mediator of angiogenesis (the formation of new blood vessels), and binds two VEGF receptors (VEGF receptor-1 and VEGF receptor-2), which are expressed on vascular endothelial cells. In healthy humans, VEGF promotes angiogenesis in embryonic development and is important in wound healing in adults. VEGF is the key mediator of angiogenesis in cancer, in which it is up-regulated by oncogene expression, a variety of growth factors and also hypoxia. Angiogenesis is essential for cancer development and growth: before a tumor can grow beyond 1–2 mm, it requires blood vessels for nutrients and oxygen. The production of VEGF and other growth factors by the tumor results in the ‘angiogenic switch’, where new vasculature is formed in and around the tumor, allowing it to grow exponentially. Tumor vasculature formed under the influence of VEGF is structurally and functionally abnormal. Blood vessels are irregularly shaped, tortuous, have dead ends and are not organized into venules, arterioles and capillaries. They are also leaky and hemorrhagic, which leads to high interstitial pressure. These characteristics mean that tumor blood flow is suboptimal, resulting in hypoxia and further VEGF production. This central role of VEGF in the production of tumor vasculature makes it a rational target for anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Self-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Self-citationHeterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Developmental regulation of the growth plate
Kronenberg, H. M. (2003) · Nature · doi:10.1038/nature01657 · Cited by 2,849
Cited by
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Kim, N., Kim, H. K., Lee, K., Hong, Y., Cho, J. H., Choi, J. W., Lee, J.-I., Suh, Y.-L., Ku, B. M., Eum, H. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16164-1 · Cited by 1,274
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Actin and Actin-Binding Proteins
Pollard, T. D. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018226 · Cited by 912
Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease
Ranganath, S. H., Levy, O., Inamdar, M. S., & Karp, J. M. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.02.005 · Cited by 809
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Holmquist-Mengelbier, L., Fredlund, E., Löfstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, Å., Gradin, K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.026 · Cited by 735
Tumor microenvironment: The role of the tumor stroma in cancer
Li, H., Fan, X., & Houghton, J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21159 · Cited by 646
Metabolic Regulation of Macrophage Polarization in Cancer
Mehla, K., & Singh, P. K. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.10.007 · Cited by 617
VEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578
Recent advances in biosensor development for the detection of cancer biomarkers
Jayanthi, V. S. P. K. S. A., Das, A. B., & Saxena, U. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.12.014 · Cited by 565
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 554
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 522
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
Hypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
Ion channels and the hallmarks of cancer
Prevarskaya, N., Skryma, R., & Shuba, Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.005 · Cited by 448
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Posttranscriptional regulation of cancer traits by HuR
Abdelmohsen, K., & Gorospe, M. (2010) · WIREs RNA · doi:10.1002/wrna.4 · Cited by 412
Dietary modifications for enhanced cancer therapy
Kanarek, N., Petrova, B., & Sabatini, D. M. (2020) · Nature · doi:10.1038/s41586-020-2124-0 · Cited by 411
The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 407
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Hypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 394
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression
Piccard, H., Muschel, R. J., & Opdenakker, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.06.004 · Cited by 373
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
Lee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis
Xu, Z., Vonlaufen, A., Phillips, P. A., Fiala-Beer, E., Zhang, X., Yang, L., Biankin, A. V., Goldstein, D., Pirola, R. C., Wilson, J. S., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090899 · Cited by 356
An overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
Wang, J., Li, D., Cang, H., & Guo, B. (2019) · Cancer Medicine · doi:10.1002/cam4.2327 · Cited by 349
The Molecular Pathogenesis of Osteosarcoma: A Review
Broadhead, M. L., Clark, J. C. M., Myers, D. E., Dass, C. R., & Choong, P. F. M. (2011) · Sarcoma · doi:10.1155/2011/959248 · Cited by 346
Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
Boopathy, G. T. K., & Hong, W. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00049 · Cited by 344
Liao, D., Corle, C., Seagroves, T. N., & Johnson, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2701 · Cited by 339
Menstrual physiology: implications for endometrial pathology and beyond
Maybin, J. A., & Critchley, H. O. D. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv038 · Cited by 337
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
Sato, Y., Goto, Y., Narita, N., & Hoon, D. S. B. (2009) · Cancer Microenvironment · doi:10.1007/s12307-009-0022-y · Cited by 319
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
Nanoparticles' interactions with vasculature in diseases
Tee, J. K., Yip, L. X., Tan, E. S., Santitewagun, S., Prasath, A., Ke, P. C., Ho, H. K., & Leong, D. T. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00309f · Cited by 314
3D Bioprinting a Cell-Laden Bone Matrix for Breast Cancer Metastasis Study
Zhou, X., Zhu, W., Nowicki, M., Miao, S., Cui, H., Holmes, B., Glazer, R. I., & Zhang, L. G. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b10673 · Cited by 307
A Cell-Based Model Exhibiting Branching and Anastomosis during Tumor-Induced Angiogenesis
Bauer, A. L., Jackson, T. L., & Jiang, Y. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.101501 · Cited by 297
Nanopreparations for organelle-specific delivery in cancer
Biswas, S., & Torchilin, V. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.004 · Cited by 292
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer
Yang, Z., Wang, T., Wu, D., Min, Z., Tan, J., & Yu, B. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01714-8 · Cited by 264
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Carbon‐Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment
Saleem, J., Wang, L., & Chen, C. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800525 · Cited by 262
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Neuropilin 1: function and therapeutic potential in cancer
Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1500-0 · Cited by 233
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Elgundi, Z., Papanicolaou, M., Major, G., Cox, T. R., Melrose, J., Whitelock, J. M., & Farrugia, B. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01482 · Cited by 176
Iron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95
Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., Higuera, M., Pfister, D., Ramadori, P., Pinyol, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.028 · Cited by 92
Cardiovascular Importance of the MicroRNA‐23/27/24 Family
BANG, C., FIEDLER, J., & THUM, T. (2012) · Microcirculation · doi:10.1111/j.1549-8719.2011.00153.x · Cited by 90
STIM-Orai Channels and Reactive Oxygen Species in the Tumor Microenvironment
Frisch, J., Angenendt, A., Hoth, M., Prates Roma, L., & Lis, A. (2019) · Cancers · doi:10.3390/cancers11040457 · Cited by 68
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“These characteristics lead to generating more hypoxia and thus more VEGF production [123].”
BackgroundRepurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Fu, C., Tyagi, R., Chin, A. C., Rojas, T., Li, R.-J., Guha, P., Bernstein, I. A., Rao, F., Xu, R., Cha, J. Y., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.311983 · Cited by 28
The Role of WAVE2 Signaling in Cancer
Rana, P. S., Alkrekshi, A., Wang, W., Markovic, V., & Sossey-Alaoui, K. (2021) · Biomedicines · doi:10.3390/biomedicines9091217 · Cited by 25
“VEGF is known to induce tumor growth through angiogenesis [130].”
BackgroundNakanishi, K., Hiramoto, K., & Ooi, K. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00089 · Cited by 18
Metadata
- Authors
- Carmeliet, P.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 69
- Issue
- Suppl. 3
- Pages
- 4-10
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W1972739162
- Cited by
- 1,768
- References
- 45
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.